Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tc-6987. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 12/20 | 0.83 |
| ▸ | CHRNB2 | P17787 | 14/20 | 0.85 |
| ▸ | CHRNA4 | P43681 | 14/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tc-6987 SCHEMBL1741518 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL29463330 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL1742025 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL29463329 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL1459637 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL1460452 | 1.00 | CHRNB2 (0.85) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL2546087 | 0.99 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL1741470 | 0.99 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL2546082 | 0.99 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNA7 | |
| Tc-6987 SCHEMBL1741468 | 0.99 | CHRNB2 (0.84) | CHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2389378-B1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT INC (US) | 2014-06-25 | — | — | EP | claimed |
| US-8476296-B2 | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide | TARGACEPT, INC. (US) | 2013-07-02 | — | — | US | claimed |
| EP-2389378-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | Targacept, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| US-20110257224-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC (US) | 2011-10-20 | — | — | US | claimed |
| US-8038426-B2 | Injection mold friction puller | PROGRESSIVE COMPONENTS INTERNATIONAL CORPORATION (US) | 2011-10-18 | — | — | US | claimed |
| WO-2010085724-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC. (US) | 2010-07-29 | — | — | WO | claimed |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | ATTENUA, INC. | 2017-05-04 | — | — | US | disclosed |
| US-9173876-B2 | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide | ATTENUA, INC. | 2015-11-03 | — | — | US | disclosed |
| US-20150105421-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | ATTENUA, INC. | 2015-04-16 | — | — | US | disclosed |
| US-8901151-B2 | Preparation and therapeutic applications of (2S, 3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]OCT-3-yl)-3,5-difluorobenzamide | TARGACEPT, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2389378-B1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-20140163065-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2647373-A1 | Methods for preventing the development of retinopathy by the oral administration of exo-S-mecamylamine. | Targacept, Inc. (US) | 2013-10-09 | — | — | EP | disclosed |
| EP-2389378-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | Targacept, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110257224-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC (US) | 2011-10-20 | — | — | US | disclosed |
| US-8038426-B2 | Injection mold friction puller | PROGRESSIVE COMPONENTS INTERNATIONAL CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | Targacept ,Inc (US) | 2011-04-28 | — | — | US | disclosed |
| EP-2296640-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | Targacept Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| WO-2010085724-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | TARGACEPT, INC. (US) | 2010-07-29 | — | — | WO | disclosed |
| WO-2009140201-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | TARGACEPT, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105421-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | CHRNA2, CHRNA3, CHRNB2 | CHRNA7 9/4885CHRNB2 3/4885CHRNA4 7/4885 |
| US-20140163065-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S, 3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | CHRNA2, CHRNA3, CHRNB2 | CHRNA7 9/4885CHRNB2 3/4885CHRNA4 7/4885 |
| US-20110098312-A1 | METHODS FOR PREVENTING THE DEVELOPMENT OF RETINOPATHY BY THE ORAL ADMINISTRATION OF NNR LIGANDS | CHRNA10, CHRNA5, CHRNB2 | CHRNA7 6/4885CHRNB2 3/4885CHRNA4 10/4885 |
| US-20110257224-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | CHRNA2, CHRNA3, CHRNA5 | CHRNA7 8/4885CHRNB2 4/4885CHRNA4 7/4885 |
| US-20170119746-A1 | PREPARATION AND THERAPEUTIC APPLICATIONS OF (2S,3R)-N-2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)-3,5-DIFLUOROBENZAMIDE | CHRNA2, CHRNA3, CHRNB2 | CHRNA7 9/4885CHRNB2 3/4885CHRNA4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.